Enzyme

Caldic announces partnership with BIO-CAT to bring innovative probiotics to the Companion Animal Health and Nutrition industry

Retrieved on: 
Tuesday, January 16, 2024
Animal, Health, Partnership, Nutrition, Fermentation, Human, Enzyme, FDA, Antioxidant, Pet industry

This agreement secures a rapid go-to-market strategy for BIO-CAT, leveraging Caldic's leadership position in the Companion Animal market as a provider of value-add antioxidant, vitamin, mineral, and ingredient solutions.

Key Points: 
  • This agreement secures a rapid go-to-market strategy for BIO-CAT, leveraging Caldic's leadership position in the Companion Animal market as a provider of value-add antioxidant, vitamin, mineral, and ingredient solutions.
  • The company offers an extensive range of single-to-multi-enzyme blends and unique microbial solutions for better animal digestive health.
  • "This partnership with BIO-CAT significantly strengthens Caldic's existing Companion Animal portfolio," says Liz Parker, Director of Companion Animal Health & Nutrition, Caldic North America, "adding a range of innovative and customizable solutions to inspire quality pet food and health.
  • "We value Caldic's commitment to the Companion Animal space and their ability to scale our OPTIFEED® probiotic business within their customer base.

Global Synthetic Biology Market Analysis and Forecast to 2028 - Market Harnesses AI, Leads Growth in Asia Pacific, and Offers Novel Healthcare Solutions - ResearchAndMarkets.com

Retrieved on: 
Wednesday, January 10, 2024
Health, Biotechnology, SynBio, Research, Growth, Synthetic biology, DNA, Knowledge, Global health, CRISPR, Agriculture, Application, Medicine, AI, Ecosystem, User (computing), Environment, Enzyme, COVID-19, Prevalence, Therapy, Boehringer Ingelheim, DSM-IV codes, Pharmaceutical industry

The latest comprehensive analysis of the Global Synthetic Biology Market reveals significant growth and trends that are shaping the industry's future.

Key Points: 
  • The latest comprehensive analysis of the Global Synthetic Biology Market reveals significant growth and trends that are shaping the industry's future.
  • This marks an accelerated growth and reflects the evolving influence of synthetic biology across various sectors.
  • The latest research findings delineate fundamental transformations within the synthetic biology market, shedding light on burgeoning segments, technological progress, and the resultant socio-economic impacts.
  • The industry stands on the cusp of breakout growth, with an ever-deepening commitment to improving global health and environment through synthetic biology innovations.

Experiments in Infant Mice Suggest New Way to Prevent Spread of Flu in People

Retrieved on: 
Thursday, January 11, 2024
Acid, Infection, Research, Neuraminidase, Jan, Mouse, Dicarboxylic acid, SAS, Society, Infant, Bacteria, NYU, MBio, Human, Enzyme, Virus, NYU Langone Health, Doctor of Philosophy, National Institutes of Health, Vaccine, Bangladesh Technical Education Board, Mammal, Cell

Viral particles, for instance, can attach to these molecules, called sialic acids, or SAs, like keys fitting into locks.

Key Points: 
  • Viral particles, for instance, can attach to these molecules, called sialic acids, or SAs, like keys fitting into locks.
  • Such infections are the main cause of the seasonal flu that kills more than 36,000 Americans annually.
  • While vaccines to guard against infection and symptom treatments exist, they are not foolproof, scientists say, and more strategies are needed to prevent infection from spreading.
  • "If further experiments in humans prove successful, desialylating neuraminidase enzymes may prevent the flu from spreading," said Ortigoza," said lead study investigator and infectious disease specialist Mila Ortigoza, MD.

WILLOW PLANS FOR SIGNIFICANT GROWTH IN 2024 ON THE BACK OF A SUCCESSFUL 2023

Retrieved on: 
Wednesday, January 10, 2024
Budesonide, WLLW, DNA, Partnership, API, Outline, TSX, Acceleration, Enzyme, Hydrocortisone, HTP, UDCA, CDMO, Prednisolone, Growth, Fine chemical

"2023 was a transformative year for Willow with the successful development of our highly valuable BioOxi technology platform which we believe will support significant growth in 2024.

Key Points: 
  • "2023 was a transformative year for Willow with the successful development of our highly valuable BioOxi technology platform which we believe will support significant growth in 2024.
  • We also generated record revenue growth through partnerships and implemented a successful corporate and operational reorganization to support the future growth of Willow," said Dr. Chris Savile, Willow's President & CEO.
  • Record revenues in 2023: Revenues increased approximately 60% to an estimated $1.3 million in 2023.
  • Significant increase in revenues: Full year R&D revenues for 2024 are expected to increase by over 100% compared to 2023.

Kanazawa University research: Researchers observe what ubiquitination hinges on

Retrieved on: 
Wednesday, January 10, 2024
American Chemical Society, E6, Nano Letters, DNA, Structural dynamics, E pluribus unum, Tissue, Cervical cancer, Takeda, Signal transduction, Kanazawa University, Enzyme, Fig, Protein, AFM, Observation, E6AP, Cysteine, HPV, Microscope

KANAZAWA, Japan, Jan. 10, 2024 /PRNewswire/ -- Researchers at Nano Life Science Institute (WPI-NanoLSI), Kanazawa University report in Nano Letters how the flexibility of a protein hinge plays a crucial role in the transfer of proteins in key cell processes.

Key Points: 
  • KANAZAWA, Japan, Jan. 10, 2024 /PRNewswire/ -- Researchers at Nano Life Science Institute (WPI-NanoLSI), Kanazawa University report in Nano Letters how the flexibility of a protein hinge plays a crucial role in the transfer of proteins in key cell processes.
  • Ubiquitination – the addition of the protein ubiquitin - is a key stage in many cell processes, such as protein degradation, DNA repairs, and signal transduction.
  • Using high-speed atomic force microscopy (HS-AFM) and molecular modelling, researchers led by Hiroki Konno and Holger Flechsig at WPI-NanoLSI, Kanazawa University have identified how the mobility of a ubiquitination related enzyme hinge allows ubiquitination to take place.
  • In the 2000s Toshio Ando at Kanazawa University was able to improve the scanning speed to such an extent that moving images could be captured.

Kanazawa University research: Researchers observe what ubiquitination hinges on

Retrieved on: 
Wednesday, January 10, 2024
American Chemical Society, E6, Nano Letters, DNA, Structural dynamics, E pluribus unum, Tissue, Cervical cancer, Takeda, Signal transduction, Kanazawa University, Enzyme, Fig, Protein, AFM, Observation, E6AP, Cysteine, HPV, Microscope

KANAZAWA, Japan, Jan. 10, 2024 /PRNewswire/ -- Researchers at Nano Life Science Institute (WPI-NanoLSI), Kanazawa University report in Nano Letters how the flexibility of a protein hinge plays a crucial role in the transfer of proteins in key cell processes.

Key Points: 
  • KANAZAWA, Japan, Jan. 10, 2024 /PRNewswire/ -- Researchers at Nano Life Science Institute (WPI-NanoLSI), Kanazawa University report in Nano Letters how the flexibility of a protein hinge plays a crucial role in the transfer of proteins in key cell processes.
  • Ubiquitination – the addition of the protein ubiquitin - is a key stage in many cell processes, such as protein degradation, DNA repairs, and signal transduction.
  • Using high-speed atomic force microscopy (HS-AFM) and molecular modelling, researchers led by Hiroki Konno and Holger Flechsig at WPI-NanoLSI, Kanazawa University have identified how the mobility of a ubiquitination related enzyme hinge allows ubiquitination to take place.
  • In the 2000s Toshio Ando at Kanazawa University was able to improve the scanning speed to such an extent that moving images could be captured.

A Second-Generation Nutrition Brand Launches Dr. Siegal's® Just Enough™ Multivitamins for People Who Don't Want to Take More Vitamins than They Need

Retrieved on: 
Tuesday, January 9, 2024
Dicarboxylic acid, Obesity, Just, Nutrient, Mineral, Vitamin, Enzyme, Reference Daily Intake, DV, Dietary supplement

NORTH BETHESDA, Md., Jan. 9, 2024 /PRNewswire/ -- Dr. Siegal's, a second-generation nutrition brand by Nutraforia, today announced the forthcoming launch of its Dr. Siegal's Just Enough "recommended potency" multivitamin product line. Unlike vitamin brands that pack in hundreds or thousands of times the recommended Daily Value, Dr. Siegal's Just Enough provides no more than 100 percent of the recommended DV of 27 vitamins, minerals, amino acids, and enzymes.

Key Points: 
  • Dr. Siegal's Just Enough multivitamins provide no more than 100 percent of the recommended Daily Value of 27 nutrients.
  • They provide no more than the recommended amounts of a broad spectrum of nutrients," said Matthew Siegal, CEO of Nutraforia, owner of the Dr. Siegal's brand.
  • "For people who aren't comfortable taking massive amounts of vitamins, Dr. Siegal's Just Enough multivitamins are a sensible alternative."
  • Today, the brand is part of Nutraforia, a personal care and wellness company founded and led by Dr. Siegal's son, Matthew Siegal.

Human medicines European public assessment report (EPAR): Zejula, niraparib, Date of authorisation: 16/11/2017, Revision: 32, Status: Authorised

Retrieved on: 
Tuesday, January 9, 2024
Medical Subject Headings, Diarrhea, Marketing, Platinum, INN, Peritoneum, Constipation, Fatigue, Woman, Ovarian cancer, ATC, Insomnia, Hypertension, Capsule, International, Cough, Tubing (recreation), Weakness, Headache, Disease, Nausea, Neutropenia, Language, DNA, Mouth, Cancer, Neoplasm, Thrombocytopenia, Abdomen, Dizziness, Platelet, PARP, Neutrophil, Appetite, European Medicines Agency, Back pain, Uterus, Enzyme, Select, Cell, Patient, Time, Safety, Anatomy, Anemia, Arthralgia, Vomiting, IIA, Periodic breathing

Human medicines European public assessment report (EPAR): Zejula, niraparib, Date of authorisation: 16/11/2017, Revision: 32, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Zejula, niraparib, Date of authorisation: 16/11/2017, Revision: 32, Status: Authorised

Hansa Biopharma provides update on business and key financials ahead of the JP Morgan Healthcare Conference

Retrieved on: 
Saturday, January 6, 2024
Marketing, Repeat, Conference, Partnership, Kidney transplantation, Trial of the century, Sarepta Therapeutics, DMD, Imlifidase, Growth, ANCA, Enzyme, Patient, Duchenne muscular dystrophy, Hansa, Immunoglobulin G, Neutron, Pharmaceutical industry

Søren Tulstrup, President and CEO, Hansa Biopharma said: "Hansa enters 2024 in a strong position to successfully execute on our key priorities.

Key Points: 
  • Søren Tulstrup, President and CEO, Hansa Biopharma said: "Hansa enters 2024 in a strong position to successfully execute on our key priorities.
  • We also continue to expand access to imlifidase for highly sensitized kidney transplant patients through a new commercial partnership with NewBridge in the MENA region.
  • Management will be available for meetings in San Francisco during the J.P. Morgan Conference week, January 8-11, 2024.
  • Susan Noonan is coordinating the schedule on behalf of Hansa Biopharma and can be reached at [email protected] .

Hansa Biopharma provides update on business and key financials ahead of the JP Morgan Healthcare Conference

Retrieved on: 
Saturday, January 6, 2024
Marketing, Repeat, Conference, Partnership, Kidney transplantation, Trial of the century, Sarepta Therapeutics, DMD, Imlifidase, Growth, ANCA, Enzyme, Patient, Duchenne muscular dystrophy, Hansa, Immunoglobulin G, Neutron, Pharmaceutical industry

Søren Tulstrup, President and CEO, Hansa Biopharma said: "Hansa enters 2024 in a strong position to successfully execute on our key priorities.

Key Points: 
  • Søren Tulstrup, President and CEO, Hansa Biopharma said: "Hansa enters 2024 in a strong position to successfully execute on our key priorities.
  • We also continue to expand access to imlifidase for highly sensitized kidney transplant patients through a new commercial partnership with NewBridge in the MENA region.
  • Management will be available for meetings in San Francisco during the J.P. Morgan Conference week, January 8-11, 2024.
  • Susan Noonan is coordinating the schedule on behalf of Hansa Biopharma and can be reached at [email protected] .